LAWRENCE, Mass., May 20, 2015 /PRNewswire/ -- NxStage
Medical, Inc. (Nasdaq: NXTM) yesterday announced the Company's
first annual Zenith Award winners, the critical care nurses in the
Cardiovascular Intensive Care Unit (CVICU) at Medical City Dallas
Hospital (MCDH). As a leading manufacturer of dialysis products,
NxStage created the Zenith Award to recognize critical care nurses
who deliver outstanding renal care to patients. NxStage is proud to
recognize this group for their ability to improve timeliness of
renal therapy for these patients, improve accuracy, and increase
staff competency.
The critical care team at MCDH achieved these results by
involving physicians in catheter placement to reduce potential
renal replacement treatment delays, collaborating with other ICU
managers to extend training programs and reduce potential errors,
and organized multiple hands-on learning opportunities to increase
staff competency with the NxStage System One. Megan Brunson, RN
Manager of MCDH's CVICU, submitted a nomination for the award on
behalf of her team who proudly accepted it at a NxStage-sponsored
educational event during the NTI & Critical Care Exposition in
San Diego on May 19, 2015.
"The CVICU bedside staff articulated the need for excellence in
the care of the renal patient and championed a multi-disciplinary
approach," said Brunson. "As the flagship hospital of the North
Texas Division of HCA, Medical City CVICU is honored to accept this
award and continue to collaborate with NxStage on the improvement
of care in this population of patients."
"NxStage is proud to recognize the accomplishments of critical
care nurses for their dedication to patients," said NxStage
President, Joe Turk. "NxStage
recognizes how stressful the ICU environment is for critical care
nurses and so we make it our mission to help simplify the delivery
of renal replacement therapy through our technology. We
applaud the CVICU at Medical City Dallas, and all of the
applicants, for their achievements."
About NxStage Medical
NxStage Medical
Inc. (Nasdaq: NXTM) is a medical device company, headquartered
in Lawrence, Massachusetts,
USA, that develops, manufactures and markets innovative
products for the treatment of ESRD and acute kidney failure. For
more information on NxStage and its products, please visit the
Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including the Quarterly Report on Form 10-Q for the
quarter ended March 31, 2015. NxStage is under no obligation
to (and expressly disclaims any such obligation to) update or alter
its forward-looking statements, whether as a result of new
information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Tel: (978) 332-5923
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-announces-first-annual-zenith-award-winner-300086477.html
SOURCE NxStage Medical, Inc.